acalabrutinib vs ibrutinib in r/r cll: assessing the burden of adverse events
Published 1 year ago • 222 plays • Length 1:53Download video MP4
Download video MP3
Similar videos
-
1:05
final analysis of the alpine trial: zanubrutinib vs ibrutinib in r/r cll
-
1:19
acalabrutinib vs ibrutinib in previously untreated high-risk cll
-
3:20
matching-adjusted indirect comparisons of acalabrutinib vs ibrutinib in treatment-naïve cll
-
2:57
selecting between ibrutinib, acalabrutinib and zanubrutinib in the frontline setting in cll
-
2:52
first results of head-to-head acalabrutinib versus ibrutinib in cll
-
3:11
btk inhibitors for cll: acalabrutinib vs ibrutinib
-
1:55
the alpine trial shows improved outcomes with zanubrutinib versus ibrutinib in r/r cll
-
1:26
common side-effects of btk inhibitors (ibrutinib and acalabrutinib) in the treatment of cll
-
6:48
patient selection for treatment with ibrutinib in cll
-
5:59
6-year results of cll14: venetoclax-obinutuzumab for previously untreated cll
-
5:44
acalabrutinib versus ibrutinib for cll
-
2:29
real-world comparison of ttnt with ibrutinib or acalabrutinib in cll
-
2:58
results of a phase ib study of ibrutinib obinutuzumab in r/r cll
-
3:58
phase ib/iia study of azd4573 acalabrutinib in r/r dlbcl
-
1:29
bellwave-011: nemtabrutinib vs ibrutinib/acalabrutinib in treatment-naïve cll/sll
-
1:00
ash 2022 lba: results from final analysis of alpine - zanubrutinib vs ibrutinib for r/r cll/sll
-
1:33
zanubrutinib for ibrutinib/acalabrutinib intolerant r/r b-cell malignancies
-
2:09
real-world incidence of ibrutinib-related cardiotoxicity in cll: insights from the lls registry
-
3:46
the characteristics and mode of action of ibrutinib for cll
-
4:55
first results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated ch...
-
1:23
interim analysis of the flair study: efficacy of ibrutinib plus venetoclax in ighv unmutated cll
-
3:19
zanubrutinib and acalabrutinib for cll: potential alternatives to ibrutinib?